Levels of glial fibrillary acidic protein (GFAP), a marker of damage to specific neuron-supporting cells, in the fluid surrounding the…
Articles by Patricia Inácio, PhD
The biopharmaceutical UCB and Aitia have joined forces to accelerate the development of a novel Huntington’s disease…
Reduced levels of oxytocin — a natural hormone produced in the brain’s hypothalamus that also works as a chemical messenger…
Researchers have developed a new therapy that reduced the toxic buildup of the mutant huntingtin (HTT) protein — the hallmark…
Abnormal red blood cells, known as acanthocytosis, were identified in four unrelated Chinese adults with Huntington’s disease —…
ProQR Therapeutics’ experimental therapy QRX-704 significantly reduced levels of the toxic huntingtin (HTT) protein clumps that fuel Huntington’s…
A recent report describes the case of a Chinese woman with a family history of Huntington’s disease (HD) who…
Bit.Bio has launched a new human cell model to advance research and accelerate therapeutic development for Huntington’s…
A Phase 2 trial evaluating PTC518, an investigational treatment for Huntington’s disease, has started in the U.S.,…
Annexon’s investigational therapy ANX005 is showing tolerability and a potential to treat people in the earlier stages of Huntington’s…